How do pan-RAS inhibitors like daraxonrasib differ from KRAS G12C inhibitors like sotorasib and adagrasib, and why has r

The primary distinction between these two classes of inhibitors lies in their breadth of target and their mechanism of binding.

Pan-RAS vs. KRAS G12C Inhibitors

• KRAS G12C Inhibitors (e.g., sotorasib, adagrasib): These are mutation-specific. They were designed to covalently bind to the cysteine residue created by the G12C mutation (a substitution of glycine with cysteine at position 12). Because they rely on this specific chemical handle, they are effective only in tumors harboring this exact mutation and cannot inhibit wild-type RAS or other common mutant variants (like G12D or G12V).
• Pan-RAS Inhibitors (e.g., daraxonrasib): These are designed to target a broader spectrum of RAS isoforms (KRAS, NRAS, HRAS) and often multiple mutation variants (including G12D, G12V, and others). Rather than relying on a single, specific mutation like G12C, they often target the highly conserved regions of the RAS protein—such as the switch II pocket—across various oncogenic states. They aim to block the "on" state of the protein regardless of the specific amino acid substitution.

Why Resistance Limits G12C Inhibitors

Clinical experience with sotorasib and adagrasib has shown that while they are effective initially, tumors frequently develop resistance. The limitations generally fall into three categories:

1. On-Target Mutations: The cancer cells may acquire secondary mutations in the KRAS gene itself (such as Y96D/C or H95D/R/Q) that sterically hinder the inhibitor from binding to the G12C pocket, effectively rendering the drug unable to latch onto the protein.
2. Pathway Bypass (Adaptive Resistance): RAS signaling is part of a redundant network. When KRAS G12C is inhibited, the cell often compensates by upregulating parallel signaling pathways—such as PI3K/AKT, EGFR, or SHP2—to maintain growth and survival. By "re-routing" their signals, the cells bypass the need for the specific KRAS G12C protein that the drug is targeting.
3. Amplification: Some tumors amplify the mutated KRAS G12C gene copy number, producing more mutant protein than the administered dose of the inhibitor can feasibly saturate.

Pan-RAS inhibitors seek to address some of these limitations by hitting a broader range of RAS drivers and potential bypass mechanisms, though they face their own challenges, particularly regarding the need for high potency without causing toxicity by inhibiting "healthy" wild-type RAS in normal tissues.